Skip to content

Ultrasonic Neuromodulation for Treatment of Cognitive Impairment

Deep Brain Therapy With Low-intensity Ultrasound for Treatment of Cognitive Impairment

Status
Terminated
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06135051
Enrollment
1
Registered
2023-11-18
Start date
2024-08-18
Completion date
2024-08-21
Last updated
2025-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Cognitive Impairment, Dementia

Brief summary

This study will evaluate a new form of non-invasive deep brain therapy for individuals with Alzheimer's disease. Low-intensity transcranial focused ultrasound stimulation will first be delivered using a range of stimulation parameters during psychophysical and physiological monitoring. A well-tolerated stimulation protocol will be selected for subsequent testing in a blinded randomized sham-controlled cross-over trial. The trial will evaluate brain target engagement using magnetic resonance imaging, PET imaging, and numerical scales of cognitive performance.

Interventions

The device delivers low-intensity ultrasonic waves into specific brain targets.

Sponsors

University of Utah
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Mild cognitive impairment or mild dementia due to Alzheimer's disase (AD) with confirmed AD biomarkers (Amyloid PET or CSF) * Age 65-80 * MOCA \> 18

Exclusion criteria

* Evidence of cerebral amyloid angiopathy or stroke within 1 year * Clinical symptoms or findings suggestive of alternative diagnosis or co-pathology * Inability to complete MRI * Suicidal ideation

Design outcomes

Primary

MeasureTime frameDescription
Montreal Cognitive Assessment Test for Dementia (MoCA)Up to 3 months following study initiationThe MoCA is a 30-point test to detect cognitive impairment. Scores range from 0 (poor) and 30 (perfect).
Hamilton Depression Rating Scale (HDRS-17)Up to 3 months following study initiationThis 17-item questionnaire rates the severity of depression by probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. The scores range from 0 (no symptoms) to 52 (worst possible).
Amyloid PETUp to 3 months following study initiationPET (positron emission tomography) combined with fluorine-18 labelled radiotracers provide brain scans that are interpreted as either amyloid-beta positive or negative.

Secondary

MeasureTime frameDescription
Hopkins Verbal Learning Test-Revised (HVLT-R)Up to 3 months following study initiationHVLT-R is a verbal memory test with 12 words learned over three trials, with the correct words summed for the Total Recall score (range = 0 (worst) - 36 (best)). The Delayed Recall score is the number of correct words recalled after a 20 - 25-minute delay (range = 0 (worst) - 12 (best)).
Digit Span Memory TestUp to 3 months following study initiationA standard test for working memory. In this test, a list of random numbers or letters is presented on a computer screen at the rate of one per second. The test begins with three numbers, increasing until the person commits errors. The average digit span for normal adults without error is seven plus or minus two. The higher the number, the more patent the working memory.
Trail Making Test, Part A and BUp to 3 months following study initiationThe test probes visual scanning and working memory. The task is to connect a set of 25 dots as quickly as possible while maintaining accuracy. The faster the completion of Part A and Part B, the better.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026